Tags: Drug.

Laninamivir (CS-8958) is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. It is currently in Phase III clinical trials. It is a long-acting neuraminidase inhibitor administered by nasal inhalation.Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo.

Laninamivir.svg
ATC prefix
none
CAS number
203120-17-6
FDA UNII code
B408IW3GL5
IUPAC name
(4S5R6R)-5-acetamido-4-carbamimidamido-6-[(1R2R)-3-hydroxy-2-methoxypropyl]-56-dihydro-4H-pyran-2-carboxylic acid
PubChem
502272

Loading...

This page contains content from the copyrighted Wikipedia article "Laninamivir"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.